SMN2 and proximal spinal muscular atrophy: Restrictions related to age, number of SMN2 gene copies, and functional status, as well as the exclusion of late-onset forms such as SMA types 3 and 4, contributed to the Brazilian experience in treating SMA with disease-modifying therapies distinguishing it from that of many other countries.